Actively Recruiting

Age: 50Years - 75Years
All Genders
ID06949865

Clinical Research on Optimization of Acute Levodopa Challenge Test and New Motor Paradigm Using Perception Technology and Artificial Intelligence for Parkinson's Disease and Related Disorders

Led by Beijing Tiantan Hospital · Updated on 2025-04-29

2000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

B

Beijing Tiantan Hospital

Lead Sponsor

R

Ruijin Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating a new method that combines an innovative motor test with perception technology and artificial intelligence to improve the diagnosis of Parkinson's disease and other similar conditions. This study aims to find clear diagnostic cut-off values, explore digital markers for early and different diagnosis, and create a diagnostic model using this combined approach alongside traditional motor tests and the acute levodopa challenge test. Participants include groups with confirmed or probable Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, vascular parkinsonism, drug-induced parkinsonism, corticobasal degeneration, and dementia with Lewy bodies. The study involves recording patients' motor symptoms on video and assessing them with these advanced technologies and tests to better understand diagnostic accuracy. During the study, participants will undergo examinations including the acute levodopa challenge test and video recordings of their motor symptoms. Researchers will measure outcomes such as accuracy, sensitivity, specificity, predictive values, and diagnostic odds ratios to evaluate the method. The study is observational and includes evaluations to identify useful digital biomarkers and establish a reliable diagnostic model, with participants aged 50 to 75 years involved throughout the study period.

CONDITIONS

Brief Title

AI-Enhanced Optimization of Acute Levodopa Challenge Test

Who Can Participate

Age: 50Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with Parkinson's disease according to 2015 International Movement Disorder Society criteria
  • Early-stage Parkinson's disease with Hoehn-Yahr score ≤ 2.5 or intermediate/advanced stage with score 2.5-5
  • Diagnosed with probable or confirmed multiple system atrophy based on 2022 criteria
  • Diagnosed with probable or confirmed progressive supranuclear palsy based on 2017 criteria
  • Diagnosed with vascular parkinsonism per 2004 and 2017 expert consensus
  • Diagnosed with drug-induced parkinsonism with reversible symptoms related to specific drugs
  • Diagnosed with probable or possible corticobasal degeneration based on 2019 Chinese criteria
  • Diagnosed with probable or possible dementia with Lewy bodies based on 2017 and 2021 criteria
  • Aged between 50 and 75 years (inclusive), any gender
  • Willing to undergo study examinations and sign informed consent
Not Eligible

You will not qualify if you...

  • Cognitive dysfunction with MMSE score less than 23
  • Unable to tolerate the levodopa challenge test
  • Serious organ failure (heart, lung, liver, kidney), malignant tumors, unstable or serious internal diseases
  • Serious behavioral problems or mental disorders
  • Unable to provide informed consent
  • Other conditions deemed unsuitable by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Diagnostic Evaluation

Duration - Single day

Participants undergo evaluation involving video recording of motor symptoms to assist in diagnosis and assessment.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 4 years

Participants are observed over time to monitor their motor symptoms and disease progression using AI-enhanced perception technology.

Trial Site Locations

Total: 1 location

1

Beijing Tiantan Hospital, Affiliated to Capital Medical University

Beijing, China, 100070

Actively Recruiting

Loading map...

Research Team

T

Tao Feng, MD

L

Lingyan Ma, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

7

Similar Trials

An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evalu...

Parkinson Disease (PD)

Actively Recruiting

1 location

Phase 1 Study to Evaluate [18F]ACI-15916 as a Potential PET ...

Parkinson's Disease (PD)

Actively Recruiting

1 location

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration...

Frontotemporal Lobar Degeneration (FTLD)

Actively Recruiting

27 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here